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Abstract This study evaluated the economic and health-related consequences of the as-needed use of a long-acting
b2-agonist with fast onset (formoterol,Oxis
1 Turbuhaler1 4?5 mg) versus a short-acting b2-agonist (terbutaline, Brica-
nyl1Turbuhaler1 0?5mg) inpatientswithmoderateto severe asthma.Amulti-national (Sweden,Norway, TheNether-
lands and Greece), multi-centre (35 centres), randomized, double-blind clinical trialwas conductedusing 362 patients on
inhaled steroidsduringa12-weekperiod.The e¡ectivenessresultswerepooled andthetotalcostsincludedestimates for
b2-agonists, inhaled steroids, oral steroids, physician visits and sick-leave.The182 patients in the formoterol group had
14404 days of exposure and 29 severe exacerbations, and the 180 patients in the terbutaline group had 13655 days of
exposure and 48 severe exacerbations.The terbutaline group had 62% more severe exacerbations thanthe formoterol
group (P0?039), basedonexposuretime.Perpatient, the calculatedtotalcostswere SEK 3386 for the formoterolgroup
and SEK 3709 for the terbutaline group over the12-week period.The conclusion is that the use of Oxis1 Turbuhaler1
instead of Bricanyl1 Turbuhaler1 for as-needed treatment is amore e¡ective treatmentgeneratingcost savings froma
societalperspective.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1131, available online at http://www.idealibrary.comon
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Asthma is a chronic illness that a¡ects individuals
throughout their lives (1). A trend towards increasing
prevalence and morbidity from asthma has been found
in several countries (2,3). Hence, the occurence of asth-
ma places an increasing economic burden on society and
the health care system (4,5); this is positively correlated
with the degree of severity of the disease (6).
Since improved control of asthma reduces consump-
tion of health care (7), there are incentives to adopt
new treatment strategies that have proven successful in
clinical trials. However, an uncritical acceptance of new
pharmaceuticals is not appropriate (8).This is of impor-
tance, since the evaluation of medical technologies
should consider not only evidence on e⁄cacy and safety
but also the costs and the relative cost-e¡ectiveness of
the alternatives (9).Received 7 February 2001and accepted in revised form15May 2001.
Correspondence should be addressed to: Fredrik Berggren,
AstraZeneca R&DLund,Clinical Science, S-22187 Lund, Sweden.Fax:
+46 46 33 75 53; E-mail: Fredrik.Berggren@ astrazeneca.comTraditional as-needed therapy for asthmawithb2-ago-
nists has the drawback of a relatively short duration of
action. In general, the duration of action is 4^5h, which
necessitates repeated inhalations to achieve adequate
therapeutic e⁄cacy (10). Hence, an as-needed therapy
with fast onset and long duration, self-managed by the
patient, has the potential of improving asthma therapy
and decreasing the number of daily inhalations. Formo-
terol, a long-acting b2-agonist, is a potent therapy for
asthma with an onset of action within 3min (which is
comparable to the onset of short-acting b2-agonists,
e.g. salbutamol and terbutaline) and a duration of 12h,
which enables twice-daily administration (11^14). Formo-
terol is recommended in guidelines for treating asthma
when adequate doses of inhaled steroid (maintenance)
treatment are insu⁄cient for controlling symptoms (15).
Several di¡erent treatment strategies have been ana-
lysed in economic evaluations, e.g. the choice of device
(16), the use of combined short-acting b2-agonist/steroids
therapy (17), the use of combined therapy with steroids
and regular use of a long-acting b2-agonist (18,19). Eco-
nomic evaluations of asthma treatments have been re-
ported in several reviews (20^22). However, to the best
754 RESPIRATORYMEDICINEof our knowledge no economic evaluation has thus far
been published on the as-needed use of a long-acting b2-
agonist with fast onset versus a short-acting b2-agonist.
This study aimed at evaluating, from a societal per-
spective, the economic andhealth related consequences,
in terms of severe exacerbations, of the as-neededuse of
a long-acting b2-agonist with fast onset (formoterol,
Oxis1 Turbuhaler1 4?5mg) versus a short-actingb2-ago-
nist (terbutaline, Bricanyl1 Turbuhaler1 0?5mg). Both
b2-agonists are used in combination with inhaled ster-
oids.
METHODSANDMATERIALS
This economic evaluation considers the costs and e¡ects
during the12-week study period.The costs included are
those for studymedications and those for severe exacer-
bations.The intention of the study was to estimate the
cost per avoided exacerbation.
The clinical study
Safety and e⁄cacy data were collected in a multi-na-
tional (Sweden, Norway,The Netherlands, and Greece),
multi-centre (35 centres), randomized, double-blindTABLE 1. Patientcharacteristics by treatmentgroup at studyen
Variable
No. randomized and treated
Mean age (years)
Gender:No. men (%)
Habitual smoker (n)
Duration of asthma (years)
Inhaled daily steroid dose (mg)*
Totalnumberof exposure days
Discontinuations
Discontinuations due to deteriorated asthma
No. of patients completed
*Meanvalue per treatmentgroup.
TABLE 2. Meannumber of inhalations of study drug per day du
the treatmentperiod.Themeanduring the run-inperiod (last 7
Variable Oxis1Turbuhaler1 4?5 mg B
Numberof inhalations 3?91
(5?07)
Inhalation occasions 3?09
(3?99)comparison of formoterol versus terbutaline in parallel
groups of patients with moderate to severe asthma.
Both therapies were administered by Turbuhaler1. The
duration of the study was12 weeks (23).
The three study objectives were: (i) to investigate if
formoterol 4?5mg (Oxis1 Turbuhaler1) is safe as as-
needed treatment; (ii) to investigate how formoterol
4?5mg as-needed can maintain or improve asthma con-
trol compared with terbutaline 0?5mg as-needed; (iii)
to compare the number of drug intake occasions be-
tween formoterol 4?5mg and terbutaline 0?5mg.
The clinical trial included 362 reversible patients on in-
haled steroids.The182 patients in the formoterol group
had14404 days of exposure to the studymedication and
the 180 patients in the terbutaline group had 13655 days
of exposure. An inhalation occasionwas de¢ned as every
time the patient felt a need for a dose of study drug to
relieve asthma symptoms and inhaled at least once, i.e.
one inhalation occasion could consist of more than one
inhalation. Table 1 reports patient characteristics by
treatment group, and Table 2 reports inhalation of study
drug during the last 28 days in the treatment period,
which was assumed to be the consumption pattern
throughout the entire study period.
During the study, 19 patients discontinued the study
medication due to adverse events, six in the formoteroltry
Oxis1
Turbuhaler1 4?5 mg
Bricanyl1
Turbuhaler1 0?5mg
182 180
46?0 48?2
88 (48) 69 (38)
27 29
16?3 17?1
890 860
14404 13655
21 32
3 8
161 148
ring treatment and inhalation occasions for the last 28 days in
days) is shownwithin brackets
ricanyl1 Turbuhaler1 0?5mg Meandi¡erence/P-value
4?78 0?76/
(5?29) 0?0005
3?78 0?63/
(4?12) 0?0003
COST-EFFECTIVENESSOF THEAS-NEEDEDUSEOFFORMOTEROLANDTERBUTALINE 755group and13 in the terbutaline group.Three serious ad-
verse events were reported, all in the terbutaline group.
The e¡ectiveness variable: severe
exacerbations
A severe exacerbation was de¢ned as the need for oral
corticosteroids, either as judged by the investigator or
following a decrease in morning peak expiratory £ow
(PEF) 30% below baseline on two consecutive days. Any
severe asthma exacerbation according to the de¢nition
above was considered as an adverse event with severe
intensity, whichmeans it was incapacitating and resulted
in the inability to perform normal activities (23). The
average duration of a severe exacerbation in the FACET
study (the Formoterol And Corticosteroids Establishing
Therapy study), conducted in a similar patientpopulation
(24), was 6?82 days (25).The FACETstudy and the study
used here have the same de¢nition of a severe exacerba-
tion. The same duration of a severe exacerbation has
been used in both treatment arms.This is supported by
the analysis of the 425 severe exacerbations in the
FACETstudy (26), which showedno di¡erences in severe
exacerbations between the treatments. For the eco-
nomic analysis of this study the data were pooled for
the four countries included in the clinical trial.
In the formoterol group, 26 patients had a ¢rst severe
exacerbation and three patients had a second one. In the
terbutaline group, 43 patients had a ¢rst severe exacer-
bation and ¢ve had a second one.The patients discontin-
ued the study after their second exacerbation. As a
consequence of this, the economic evaluationwas based
on exposure time, i.e. the costperday was calculated for
all cost categories.
The cost of treatments
To re£ect the societal cost, this study examines the di-
rect and indirect costs related to severe exacerbations.
The costdata generatedwere the cost of the studymed-
ications (Oxis1Turbuhaler1 4?5mg andBricanyl1Turbu-
haler1 0?5mg), the average treatment cost of inhaled
steroids, costs for oral steroids, costs for physician visits
and costs for sick leave. Costs were calculated in 1997
Swedish crowns (SEK)(»1SEK14,USD1SEK10, January
2001). The prices per inhalation of medications used in
this study were SEK 3?50 for formoterolOxis1Turbuha-
ler1 4?5mg (3660 doses per package), SEK 0?77 for ter-
butaline Bricanyl1 Turbuhaler1 0?5mg (200 doses per
package), and SEK 3?48 for budesonide Pulmicort1Tur-
buhaler1 400mg (200 doses per package), which are the
prices used in Swedish pharmacies.The cost for the oral
steroid, prednisolone10mg,was SEK41?50 for 25 tablets
(27).The oral steroidwasprescribed as three tablets per
day for 7 days, but the cost was calculated based on thepackage of 25 tablets due to the indivisible sales unit.For
the continuous use of drugs such as steroids and b2-ago-
nists, a calculation of costs based on the price per inhala-
tion is applicable. For costs for discrete events such as a
severe exacerbation, indivisibilities in the treatment pro-
cess ought to be taken into consideration.
The remaining direct cost was the cost of contacts
with the health-care sector in the case of a severe ex-
acerbation.This cost was assumed to be SEK 800, which
is the costof avisit to aGP according to the Swedish Fed-
eration of County Councils (L. BÌckstr˛m, pers. com-
mun.). For an estimate of the indirect cost, we followed
the practice of earlier economic evaluations of asthma
treatments (28) by using the human capital approach.
The duration of a severe exacerbation in the FACET
study was used, 6?82 days (24,25), together with the
average earnings for full time employment in 1997 ob-
tained from Statistics Sweden (SEK 17900 plus payroll
taxes per month, SCB) (29). No data on costs or re-
source consumption, except the consumption of study
medications, was collected in the clinical trial. Following
earlier economic evaluations of asthma treatment, we
assumed a zero cost for adverse events (19). The costs
for discontinuations were assumed to be zero, and the
economic evaluation was based on exposure time in or-
der to take the discontinuations into consideration.
RESULTS
The clinical results of the trial indicated thatboth formo-
terol and terbutaline were well tolerated, and that lung
function was improvedmore with formoterol than with
terbutaline (morning PEF mean di¡erence11lmin71, and
evening PEF mean di¡erence 8 lmin71). The Quality of
Life Index, SF-36, showed a di¡erence in favour of formo-
terol regarding total score. The time to ¢rst severe ex-
acerbation was prolonged in the formoterol group. The
number of severe exacerbations was 48 in the terbuta-
line group and 29 in the formoterol group. The total
number of inhalations and inhalation occasions di¡ered
between the groups. All di¡erencesmentionedwere sta-
tistically signi¢cant in favour of the formoterol treat-
ment group. No hospitalizations took place during the
study period.
The results presented inTable 3(a) re£ect the distribu-
tion of costs on a daily basis.Table 3(b) shows the results
for the12-week period.Therewere 62%more severe ex-
acerbations, based on exposure time, in the terbutaline
group compared with the formoterol group (P0?039).
From the societal perspective, the average total cost
over the 12-week period in the formoterol group was
SEK 3386 per patient and in the terbutaline group it
was SEK 3709 per patient. Hence, on average the use of
Oxis1 shows greater e¡ect and lower costs than Brica-
nyl1.This e¡ectwas gained through an increase of SEK 9
TABLE 3(a). Direct and indirectcosts, meanvalues, per patient in SEKperdaybycostcategory and treatmentgroup
Costcategory Oxis1Turbuhaler1 4?5 mg Bricanyl1 Turbuhaler1 0?5mg
Studydrugcosts 13?69 3?68
Inhaled steroids 7?74 7?48
Oral systemic steroids 0?08 0?15
Healthcare costs 1?61 2?81
Total directcost 23?12 14?12
Indirectcost 17?20 30?04
Total cost 40?32 44?16
TABLE 3(b). Direct and indirect costs, mean values, per patient in SEKper12-week period by cost category and treatment
group
Costcategory Oxis1Turbuhaler1 4?5 mg Bricanyl1 Turbuhaler1 0?5mg
Studydrugcosts 1150 309
Inhaled steroids 649 628
Oral systemic steroids 7 13
Health care costs 135 236
Total directcost 1941 1186
Indirectcost 1445 2523
Total cost 3386 3709
756 RESPIRATORYMEDICINEper patient per day in the direct costs, based on in-
creased medication costs of 10 SEK and decrease in
health care cost of1SEK.
A Poisson model was used to estimate and compare
the incidence of severe exacerbations between the
groups. The mean number of severe exacerbations in
the terbutaline group was estimated to be 1?62 times
that in the formoterol group (95% con¢dence interval
limits: 1?02^2?58). In terms of the number of severe ex-
acerbations this means that the 29 severe exacerbations
in the formoterol group correspond to a variation in the
severe exacerbations in the terbutaline group of be-
tween 30 and 75 according to the estimated con¢dence
interval. In terms of costs, this range of exacerbations re-
sults in costs for the terbutaline group that vary be-
tween SEK 2670 per patient and SEK 5276 per patient.
Comparing these cost ¢gureswith the average cost in
the formoterol group, an incremental cost e¡ectiveness
ratio of SEK 716 per avoided severe exacerbation was
found for the lower limit of the 95% con¢dence interval
[(3386^2670)/(29730)716 SEK/avoided severe exacer-
bation]. For the upper limit of the con¢dence interval
the cost in the terbutaline group could be calculated to
SEK 5276, indicating a cost-saving situation of SEK 1890
per patient.
A sensitivity analysis of the single highest cost cate-
gory, the indirect costs, showed that for durations of se-
vere exacerbations over 4?78 days (we used a value of6?82), the formoterol group cost less than the terbuta-
line group. The result allows for a 30% reduction in the
duration of a severe exacerbation or in average earnings.
The indirectcosts are considered to berather insensitive
to the duration of severe exacerbations and to average
earnings.
DISCUSSION
In this study we conducted a cost-e¡ectiveness analysis.
The costs were measured from a societal perspective.
Hence, the analysis considers both direct costs and indir-
ect costs for the evaluated treatments: the as-needed
use of a long-actingb2-agonistwith fastonset (formoter-
ol,Oxis1 Turbuhaler1 4?5mg) versus a short-acting b2-
agonist (terbutaline, Bricanyl1 Turbuhaler1 0?5mg), in
combinationwith inhaled steroids.Theresults of theclin-
ical study showed that both treatment patterns were
safe andwell tolerated (23).
In the clinical trial on which this evaluation is based,
there is considerable risk that patients used the study
medications as a matter of habit rather than based on
an actual need for the medications.The trial had a focus
on patients with a high consumption of a short-acting
bronchodilator.One inclusion criteriawas a daily need of
at least three andmaximumeight inhalation occasions of
terbutalineTurbuhaler1 0?5mgduring the run-in period.
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tionsperday.Theuse of formoterol according to thepro-
ven duration of formoterol inhaled via Turbuhaler1
indicates that some patients would require only half the
number of inhalations that were used in the clinical trial.
As a consequence of this, the costs of formoterol, in-
haled via Turbuhaler1, might be over-estimated com-
pared with an optimal treatment pattern with fewer
inhalations.The proportion of patients in the formoterol
group that used their as-needed treatment twice or less
per day increased throughout the study.
The impact of the indirect costs is critical to the out-
come of the analysis.The analysis conductedused a dura-
tion of 6?82 days per severe exacerbation.The sensitivity
analysis, however, indicates that indirect costs should be
considered rather insensitive to the duration of severe
exacerbations and to earnings. In a recently conducted
Spanish study, patients with mild, moderate and severe
asthma were reported to have lost 11?8, 19?3 and 60?7
working days, respectively, yearly (6). In Sweden the
duration of one occasion of sick-leave for the bronchitis,
emphysema and asthma disease groupwasbetween 4?75
and14?06 days (1983) (5,30).
The calculation of the indirect costs in this study
isbased on the averagewagerate for people in thework-
ing force. According to the traditional approach based
on human capital approach this could be interpreted
as that the costs for retired and students are overesti-
mated. The obvious counter argument, also based
on economic theory, is that these groups also have a
clear alternative cost from being sick and ‘‘produce’’
a contribution to society although not in terms of
payed work. Another argument re£ects upon equity
aspects.
In this analysis, the same health state is used through-
out the duration of the severe exacerbation.This might
not be the most appropriate way of modeling the dy-
namics of health states associated with a severe exacer-
bation. A more intuitive approach would be a gradual
decrease of utility at the start of a severe exacerbation
and a gradual increase of utilityduring the followingdays,
until a stable state of general health has been reached.
There is, however, no a priori reason to believe that the
total disutility, and hence the absence fromwork, would
be larger or smaller with this alternative than with the
more static approach that was used. Hence, no intrinsic
bias is attached to the method of estimation used.
Neither this theoretical reasoning nor the data pre-
sented on sick-leave render any conclusion possiblewhen
it comes to potential bias in the estimate of indirect
costs of severe exacerbations. This is an issue to be ad-
dressed in future research on health states and their dy-
namics in the ¢eld of asthma.
The duration of a severe exacerbationwas documented
from a clinical trial and the productivity loss was valued
using average earnings.This estimation procedure re£ectsthe mainstream approach.This evaluation does not, how-
ever, incorporate the bene¢ts of a reduction in mild ex-
acerbations from the use of formoterol.The bene¢ts from
a reduced number of mild exacerbations have been esti-
mated to be almost twice the size of the bene¢ts from a
reduction in costs for severe exacerbations.These results
stem from the health economic analysis of the FACET
study (18,24), which showedmore than 50 mild exacerba-
tions per severe exacerbation.The incorporation of both
mild and severe exacerbations in future economic evalua-
tions of asthma is an important issue for future research.
Adverse events, discontinuations and the exclusion of
patients who had a second severe exacerbation were
more frequent events in the terbutaline group than in
the formoterol group. Hence, there is no reason to be-
lieve that the approach used in this evaluation has sys-
tematically favoured the formoterol group. Instead, it is
more plausible that costs related to these events would
be higher in the terbutaline group.
The overall results from this cost-e¡ectiveness
study indicate that from a societal perspective the use
of Oxis1 Turbuhaler1 4?5mg as-needed is cost-saving
compared with the use of Bricanyl1 Turbuhaler1
0?5mg as-needed. This result is driven by the gains in
indirect cost speci¢ed as the average individual in
the working population. From a more narrow perspec-
tive of direct costs, a marginal expenditure of SEK 9 per
day generates a reduction in the mean number of
severe exacerbations from 0?24 per patient to 0?15 per
patient, generating reduced exacerbations, increas-
ed quality of life and cost savings from the societal
perspective.
Earlier economic evaluations have compared theuse of
formoterol as regular treatment, twice-daily, with salbu-
tamol, four times daily (19), with salmeterol twice-daily
(28), and with salbutamol, as-needed, and salmeterol,
twice-daily (31). However, this is the ¢rst economic eva-
luation published of the as-needed use of a long-acting
b2-agonist with fast onset versus a short-acting
b2-agonist.
The incremental cost-e¡ectiveness analyses compar-
ing formoterol (Oxis1) with salbutamol (31) resulted in
a cost (CAD,1997) per additional episode free day (EFD)
that was CAD 2?48 (95% con¢dence intervals74?09 to
8?65). Anearlier study (19) reported far higher incremen-
tal costs per EFD for formoterol (Foradil1), ranging
from CAD 5?67 to 7?26 (1991). Furthermore, the average
cost per EFD for formoterol (Foradil1) has been re-
ported as ranging between USD 8?50^9?00 (USD,1995)
(28).Unfortunately, this study (28) probably under-esti-
mates the average costper EFD, sincemostpatientswith
moderate asthma probably had some EFDs even when
their only medication was inhaled steroids. Taken as a
whole, this study and the studies presented here
(19,28,31) show themost favourable results for formoter-
ol (Oxis1) administered viaTurbuhaler1.
758 RESPIRATORYMEDICINECONCLUSION
The use of Oxis1Turbuhaler1 instead of Bricanyl1Turbu-
haler1 as an as-needed treatmentis amore e¡ective treat-
mentgenerating cost savings from a societal perspective.
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